The ASPRE trial evaluated which intervention for prevention of pre-eclampsia in screen-positive women (based on first-trimester combined screening)?
- A Low-dose aspirin 150 mg daily starting at 11–14 weeks ✓
- B Low-molecular-weight heparin starting at 11–14 weeks
- C Calcium supplementation 1.5 g daily from 12 weeks
- D Pravastatin 20 mg daily from 12 weeks
Correct answer: A. Low-dose aspirin 150 mg daily starting at 11–14 weeks
Explanation
The ASPRE (Aspirin for Evidence-Based Pre-eclampsia Prevention) trial demonstrated that low-dose aspirin 150 mg taken at night from 11–14 weeks significantly reduced the rate of preterm pre-eclampsia (before 37 weeks) by approximately 62% in screen-positive women. The screening algorithm used first-trimester combined testing incorporating maternal factors, uterine artery pulsatility index, mean arterial pressure, and placental growth factor.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.